<DOC>
	<DOCNO>NCT01650467</DOCNO>
	<brief_summary>The main objective study evaluate existence relationship presence certain abl polymorphism ( haplotype ) upon CML diagnosis occurrence primary resistance treatment CML imatinib .</brief_summary>
	<brief_title>Imatinib Response Patients With Chronic Myeloid Leukemia ( CML ) Function Abl Polymorphisms</brief_title>
	<detailed_description>The first secondary objective study identify , patient respond treatment , possible change polymorphisms interest course disease , reclassify polymorphisms mutation . The second secondary objective compare control patient term polymorphism frequency nonpathological abl fraction .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>The patient must give his/her inform sign consent The patient must insure beneficiary health insurance plan Inclusion Criteria CML patient Patients diagnosed CML Treatment Imatinib firstline monotherapy least 12 month RNA / cDNA use diagnosis correctly store biobank Inclusion Criteria CML patient already undergone followup visit 12 month RNA / cDNA use diagnosis/followup correctly store biobank Cytogenetic result available Absence ITK mutation primary resistance subgroup Validated compliance Inclusion Criteria optimal response group : bcrabl type less 0.1 % 12 month Inclusion criterion primary resistance group bcrabl typing &gt; 1 % and/or Philadelphia+ great 0 Inclusion Criteria control population Absence hematologic malignancy The patient participate another study The patient exclusion period determine previous study The patient judicial protection , tutorship curatorship The patient refuse sign consent It impossible correctly inform patient The patient pregnant , parturient , breastfeed The patient contraindication treatment use study Exclusion Criteria CML patient already undergone followup visit 12 month Known suspected cause resistance ( dose reduce due intolerance , digestive disease responsible malabsorption ... ) Exclusion Criteria control population History suspicion hemopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>abl polymorphism</keyword>
</DOC>